HRP20191437T1 - Sastav za kontroliranu stimulaciju jajnika - Google Patents
Sastav za kontroliranu stimulaciju jajnika Download PDFInfo
- Publication number
- HRP20191437T1 HRP20191437T1 HRP20191437T HRP20191437T1 HR P20191437 T1 HRP20191437 T1 HR P20191437T1 HR P20191437 T HRP20191437 T HR P20191437T HR P20191437 T1 HRP20191437 T1 HR P20191437T1
- Authority
- HR
- Croatia
- Prior art keywords
- product
- patient
- recombinant human
- fsh
- dose
- Prior art date
Links
- 230000002611 ovarian Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims 15
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims 15
- 210000002966 serum Anatomy 0.000 claims 9
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 6
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 6
- 208000000509 infertility Diseases 0.000 claims 6
- 230000036512 infertility Effects 0.000 claims 6
- 231100000535 infertility Toxicity 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 5
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000002474 gonadorelin antagonist Substances 0.000 claims 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims 2
- 230000009450 sialylation Effects 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal cation Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (13)
1. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu serum AMH <15 pmol/L, naznačen time da se proizvod daje u dozi od, ili ekvivalentnoj 11-13 µg rekombinantnog ljudskog FSH na dan, 12 do 16 dana nakon primjene GnRH agonista.
2. Proizvod za upotrebu prema patentnom zahtjevu 1, naznačen time da se proizvod primjenjuje u dozi od, ili ekvivalentnoj 12 µg rekombinantnog ljudskog FSH na dan.
3. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu seruma AMH >15 pmol/L, naznačen time da se proizvod primjenjuje u dozi od, ili ekvivalentnoj 0.09-0.19 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno, 12 do 16 dana nakon primjene agonista GnRH.
4. Proizvod za upotrebu prema patentnom zahtjevu 3 za liječenje pacijenta koji ima razinu seruma AMH od 15 do 24,9 pmol/L, naznačen time da se proizvod primjenjuje u dozi od 0,14 do 0,19 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno.
5. Proizvod za upotrebu prema patentnom zahtjevu 3 za liječenje pacijenta koji ima razinu seruma AMH od 25 do 34.9 pmol/L, naznačen time da se proizvod primjenjuje u dozi od, ili ekvivalentnoj 0.11 do 0.14 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno.
6. Proizvod za upotrebu prema patentnom zahtjevu 3 za liječenje pacijenta koji ima razinu seruma AMH od > 35 pmol/L, naznačen time da se proizvod primjenjuje u dozi od, ili ekvivalentnoj dozi 0,10 do 0,11 µg ljudskog izvedenog rekombinantnog FSH po kg tjelesne težine pacijenta dnevno.
7. Proizvod prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je rekombinantni ljudski FSH rekombinantni ljudski FSH koji uključuje α2, 3- i α2, 6- sijalizaciju.
8. Proizvod prema patentnom zahtjevu 7, naznačen time da 1% do 50% ukupne sijalizacije je α2, 6- sijalizacija, a 50% do 99% ukupne sijalizacije je α2.3- sijalizacija.
9. Proizvod koji da sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za uporabu u liječenju neplodnosti prema bilo kojem od prethodnih zahtjeva, naznačen time da proizvod nadalje sadrži sol koja sadrži farmaceutski prihvatljiv kation alkalijskog metala odabran iz skupine koja se sastoji od Na+ ili K+ - soli, ili njihova kombinacija.
10. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu seruma AMH <15 pmol/L, naznačen time da se proizvod daje u dozi, ili ekvivalentnoj od, 11-13 µg rekombinantnog ljudskog FSH dnevno, zajedno s antagonistom GnRH.
11. Proizvod za upotrebu prema patentnom zahtjevu 10, naznačen time da se proizvod primjenjuje u dozi od, ili ekvivalentnoj od, 12 µg rekombinantnog ljudskog FSH na dan.
12. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu seruma AMH od >15 pmol / L, naznačen time da se proizvod treba primijeniti u dozi, ili ekvivalentnoj od, 0.09-0.19 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno, zajedno s antagonistom GnRH.
13. Proizvod za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da liječenje neplodnosti sadrži korak određivanja razine seruma AMH pacijenta i korak davanja doze pacijentu koji ima specificiranu razinu seruma AMH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176803 | 2011-08-08 | ||
| EP18167552.1A EP3395357B1 (en) | 2011-08-08 | 2012-08-08 | Composition for controlled ovarian stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191437T1 true HRP20191437T1 (hr) | 2019-11-15 |
Family
ID=46785372
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230607TT HRP20230607T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20160145TT HRP20160145T1 (hr) | 2011-08-08 | 2016-02-09 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20181639TT HRP20181639T1 (hr) | 2011-08-08 | 2018-10-10 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20190023TT HRP20190023T1 (hr) | 2011-08-08 | 2019-01-03 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20191437 HRP20191437T1 (hr) | 2011-08-08 | 2019-08-08 | Sastav za kontroliranu stimulaciju jajnika |
| HRP20210277TT HRP20210277T1 (hr) | 2011-08-08 | 2021-02-18 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20210722TT HRP20210722T1 (hr) | 2011-08-08 | 2021-05-10 | Pripravak za kontroliranu stimulaciju jajnika |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230607TT HRP20230607T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20160145TT HRP20160145T1 (hr) | 2011-08-08 | 2016-02-09 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20181639TT HRP20181639T1 (hr) | 2011-08-08 | 2018-10-10 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20190023TT HRP20190023T1 (hr) | 2011-08-08 | 2019-01-03 | Pripravak za kontroliranu stimulaciju jajnika |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210277TT HRP20210277T1 (hr) | 2011-08-08 | 2021-02-18 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20210722TT HRP20210722T1 (hr) | 2011-08-08 | 2021-05-10 | Pripravak za kontroliranu stimulaciju jajnika |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9694052B2 (hr) |
| EP (9) | EP3646881B1 (hr) |
| JP (5) | JP6161609B2 (hr) |
| KR (7) | KR102014469B1 (hr) |
| CN (2) | CN107281470A (hr) |
| AR (1) | AR087476A1 (hr) |
| AU (3) | AU2012293647B2 (hr) |
| BR (2) | BR112014002884A2 (hr) |
| CA (1) | CA2844282A1 (hr) |
| CY (1) | CY1117214T1 (hr) |
| DK (8) | DK3756681T3 (hr) |
| ES (7) | ES2562648T3 (hr) |
| FI (2) | FI4005588T3 (hr) |
| HK (2) | HK1198005A1 (hr) |
| HR (7) | HRP20230607T1 (hr) |
| HU (7) | HUE062640T2 (hr) |
| IL (2) | IL300380A (hr) |
| JO (1) | JO3092B1 (hr) |
| LT (7) | LT4005588T (hr) |
| MX (2) | MX348981B (hr) |
| PL (7) | PL2821080T3 (hr) |
| PT (6) | PT2821080T (hr) |
| RS (7) | RS61672B1 (hr) |
| RU (2) | RU2613324C3 (hr) |
| SA (1) | SA112330762B1 (hr) |
| SI (7) | SI2741763T1 (hr) |
| SM (1) | SMT201600038B (hr) |
| TR (2) | TR201900071T4 (hr) |
| TW (2) | TWI555530B (hr) |
| WO (1) | WO2013020996A1 (hr) |
| ZA (2) | ZA201400952B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI532495B (zh) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| EP3237608B1 (en) * | 2014-12-22 | 2019-10-09 | F. Hoffmann-La Roche AG | Cmp-dependent sialidase activity |
| DK3662925T3 (da) * | 2015-04-17 | 2021-06-28 | Ferring Bv | Sammensætning, der omfatter fsh, til behandling af infertilitet |
| RU2719468C2 (ru) | 2015-06-26 | 2020-04-17 | Ферринг Б.В. | Способы очистки и/или вирусной инактивации |
| AU2016323541A1 (en) * | 2015-09-17 | 2018-04-12 | Glycotope Gmbh | Mammalian follicle-stimulating hormone composition with increased stability |
| WO2018060438A1 (en) * | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating female infertility |
| MX2020002235A (es) * | 2017-09-01 | 2020-07-20 | Ferring Bv | Composicion para la estimulacion ovarica controlada. |
| TW201945024A (zh) | 2018-04-30 | 2019-12-01 | 荷蘭商菲林公司 | 用於經控制之卵巢刺激的組成物 |
| TW202027780A (zh) | 2018-10-17 | 2020-08-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| US11576920B2 (en) | 2019-03-18 | 2023-02-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| CN110841060A (zh) * | 2019-11-21 | 2020-02-28 | 上海交通大学 | Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用 |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| WO2023186331A1 (en) | 2022-04-01 | 2023-10-05 | Ferring B.V. | Mixed protocol for treatment of infertility |
| WO2023227761A1 (en) | 2022-05-26 | 2023-11-30 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| WO2024008971A1 (en) | 2022-07-08 | 2024-01-11 | Ferring B.V. | Compositions and methods for intrauterine insemination (iui) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| EP1074265A1 (en) * | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
| MEP38608A (en) * | 2001-10-22 | 2011-02-10 | Merck Serono Sa | Gonadotrophins for folliculogenesis |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| US8501719B2 (en) * | 2005-11-08 | 2013-08-06 | American Infertility Of New York | Androgen treatment in females |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI532495B (zh) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| ES2547233T5 (es) * | 2010-09-29 | 2024-03-27 | Ferring Bv | Composición para su uso en el tratamiento de la esterilidad |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2012
- 2012-07-18 JO JOP/2012/0197A patent/JO3092B1/ar active
- 2012-07-23 TW TW101126453A patent/TWI555530B/zh active
- 2012-07-23 TW TW105124123A patent/TWI657822B/zh active
- 2012-08-07 AR ARP120102883A patent/AR087476A1/es not_active Application Discontinuation
- 2012-08-07 SA SA112330762A patent/SA112330762B1/ar unknown
- 2012-08-08 LT LTEP21207717.6T patent/LT4005588T/lt unknown
- 2012-08-08 PT PT14184409T patent/PT2821080T/pt unknown
- 2012-08-08 ES ES12753675.3T patent/ES2562648T3/es active Active
- 2012-08-08 FI FIEP21207717.6T patent/FI4005588T3/fi active
- 2012-08-08 KR KR1020147005938A patent/KR102014469B1/ko active Protection Beyond IP Right Term
- 2012-08-08 HU HUE20186935A patent/HUE062640T2/hu unknown
- 2012-08-08 RU RU2014102924A patent/RU2613324C3/ru active Protection Beyond IP Right Term
- 2012-08-08 BR BR112014002884A patent/BR112014002884A2/pt not_active Application Discontinuation
- 2012-08-08 PT PT201869351T patent/PT3756681T/pt unknown
- 2012-08-08 HU HUE12753675A patent/HUE027674T2/en unknown
- 2012-08-08 US US14/237,697 patent/US9694052B2/en active Active
- 2012-08-08 AU AU2012293647A patent/AU2012293647B2/en active Active
- 2012-08-08 EP EP19213649.7A patent/EP3646881B1/en active Active
- 2012-08-08 EP EP23208228.9A patent/EP4306174A3/en active Pending
- 2012-08-08 EP EP18167552.1A patent/EP3395357B1/en active Active
- 2012-08-08 HU HUE14184409A patent/HUE041769T2/hu unknown
- 2012-08-08 DK DK20186935.1T patent/DK3756681T3/da active
- 2012-08-08 CA CA2844282A patent/CA2844282A1/en active Pending
- 2012-08-08 PL PL14184409T patent/PL2821080T3/pl unknown
- 2012-08-08 LT LTEP14184409.2T patent/LT2821080T/lt unknown
- 2012-08-08 MX MX2014001489A patent/MX348981B/es active IP Right Grant
- 2012-08-08 ES ES18167552T patent/ES2742163T3/es active Active
- 2012-08-08 LT LTEP18167552.1T patent/LT3395357T/lt unknown
- 2012-08-08 HU HUE18167552 patent/HUE044610T2/hu unknown
- 2012-08-08 RS RS20210425A patent/RS61672B1/sr unknown
- 2012-08-08 HU HUE19164277A patent/HUE053716T2/hu unknown
- 2012-08-08 RS RS20230518A patent/RS64328B1/sr unknown
- 2012-08-08 DK DK12753675.3T patent/DK2741763T3/da active
- 2012-08-08 SI SI201230438T patent/SI2741763T1/sl unknown
- 2012-08-08 HU HUE17154031A patent/HUE040058T2/hu unknown
- 2012-08-08 ES ES19164277T patent/ES2871405T3/es active Active
- 2012-08-08 KR KR1020197024335A patent/KR102111514B1/ko active IP Right Grant
- 2012-08-08 WO PCT/EP2012/065507 patent/WO2013020996A1/en active Application Filing
- 2012-08-08 RS RS20181263A patent/RS57897B1/sr unknown
- 2012-08-08 PT PT212077176T patent/PT4005588T/pt unknown
- 2012-08-08 LT LTEP20186935.1T patent/LT3756681T/lt unknown
- 2012-08-08 SI SI201231884T patent/SI3566712T1/sl unknown
- 2012-08-08 SI SI201231653T patent/SI3395357T1/sl unknown
- 2012-08-08 PT PT18167552T patent/PT3395357T/pt unknown
- 2012-08-08 RS RS20210603A patent/RS61843B1/sr unknown
- 2012-08-08 PL PL17154031T patent/PL3195875T3/pl unknown
- 2012-08-08 EP EP20186935.1A patent/EP3756681B1/en active Active
- 2012-08-08 DK DK18167552.1T patent/DK3395357T3/da active
- 2012-08-08 SI SI201231398T patent/SI3195875T1/sl unknown
- 2012-08-08 LT LTEP19213649.7T patent/LT3646881T/lt unknown
- 2012-08-08 ES ES19213649T patent/ES2884947T3/es active Active
- 2012-08-08 BR BR122020001644-2A patent/BR122020001644B1/pt active IP Right Grant
- 2012-08-08 KR KR1020217023662A patent/KR102353144B1/ko active IP Right Grant
- 2012-08-08 KR KR1020217037512A patent/KR102499969B1/ko active IP Right Grant
- 2012-08-08 PL PL20186935.1T patent/PL3756681T3/pl unknown
- 2012-08-08 EP EP17154031.3A patent/EP3195875B1/en active Active
- 2012-08-08 EP EP12753675.3A patent/EP2741763B1/en active Active
- 2012-08-08 TR TR2019/00071T patent/TR201900071T4/tr unknown
- 2012-08-08 KR KR1020237004855A patent/KR20230024442A/ko not_active Application Discontinuation
- 2012-08-08 HR HRP20230607TT patent/HRP20230607T1/hr unknown
- 2012-08-08 KR KR1020207029774A patent/KR20200121918A/ko not_active Application Discontinuation
- 2012-08-08 PL PL19164277T patent/PL3566712T3/pl unknown
- 2012-08-08 ES ES17154031.3T patent/ES2692774T3/es active Active
- 2012-08-08 EP EP21207717.6A patent/EP4005588B1/en active Active
- 2012-08-08 PL PL18167552T patent/PL3395357T3/pl unknown
- 2012-08-08 ES ES14184409T patent/ES2704878T3/es active Active
- 2012-08-08 RU RU2017106756A patent/RU2739037C3/ru active Protection Beyond IP Right Term
- 2012-08-08 DK DK21207717.6T patent/DK4005588T3/da active
- 2012-08-08 PL PL12753675T patent/PL2741763T3/pl unknown
- 2012-08-08 SI SI201232033T patent/SI3756681T1/sl unknown
- 2012-08-08 DK DK19164277.6T patent/DK3566712T3/da active
- 2012-08-08 SI SI201231921T patent/SI3646881T1/sl unknown
- 2012-08-08 SI SI201231493T patent/SI2821080T1/sl unknown
- 2012-08-08 DK DK19213649.7T patent/DK3646881T3/da active
- 2012-08-08 JP JP2014524372A patent/JP6161609B2/ja active Active
- 2012-08-08 KR KR1020197036505A patent/KR20190140098A/ko not_active IP Right Cessation
- 2012-08-08 RS RS20191038A patent/RS59107B1/sr unknown
- 2012-08-08 DK DK17154031.3T patent/DK3195875T3/en active
- 2012-08-08 EP EP14184409.2A patent/EP2821080B1/en active Active
- 2012-08-08 PL PL19213649T patent/PL3646881T3/pl unknown
- 2012-08-08 CN CN201710306350.4A patent/CN107281470A/zh active Pending
- 2012-08-08 RS RS20190006A patent/RS58198B1/sr unknown
- 2012-08-08 HU HUE19213649A patent/HUE054312T2/hu unknown
- 2012-08-08 FI FIEP20186935.1T patent/FI3756681T3/fi active
- 2012-08-08 IL IL300380A patent/IL300380A/en unknown
- 2012-08-08 PT PT17154031T patent/PT3195875T/pt unknown
- 2012-08-08 LT LTEP19164277.6T patent/LT3566712T/lt unknown
- 2012-08-08 LT LTEP17154031.3T patent/LT3195875T/lt unknown
- 2012-08-08 CN CN201280038831.7A patent/CN103732243A/zh active Pending
- 2012-08-08 RS RS20160080A patent/RS54561B1/en unknown
- 2012-08-08 PT PT192136497T patent/PT3646881T/pt unknown
- 2012-08-08 DK DK14184409.2T patent/DK2821080T3/en active
- 2012-08-08 ES ES20186935T patent/ES2950911T3/es active Active
- 2012-08-08 TR TR2019/11269T patent/TR201911269T4/tr unknown
- 2012-08-08 EP EP19164277.6A patent/EP3566712B1/en active Active
-
2014
- 2014-01-28 IL IL230696A patent/IL230696B2/en unknown
- 2014-02-06 MX MX2020010991A patent/MX2020010991A/es unknown
- 2014-02-07 ZA ZA2014/00952A patent/ZA201400952B/en unknown
- 2014-11-17 HK HK14111597.8A patent/HK1198005A1/zh unknown
- 2014-11-17 HK HK15105458.7A patent/HK1204923A1/xx unknown
-
2015
- 2015-09-01 ZA ZA2015/06382A patent/ZA201506382B/en unknown
-
2016
- 2016-02-09 HR HRP20160145TT patent/HRP20160145T1/hr unknown
- 2016-02-10 SM SM201600038T patent/SMT201600038B/it unknown
- 2016-02-18 CY CY20161100142T patent/CY1117214T1/el unknown
- 2016-12-15 AU AU2016273925A patent/AU2016273925B2/en active Active
-
2017
- 2017-03-16 JP JP2017051062A patent/JP6500050B2/ja active Active
- 2017-06-29 US US15/637,962 patent/US10624953B2/en active Active
-
2018
- 2018-05-09 AU AU2018203222A patent/AU2018203222B2/en active Active
- 2018-10-10 HR HRP20181639TT patent/HRP20181639T1/hr unknown
- 2018-12-27 JP JP2018243912A patent/JP6718951B2/ja active Active
-
2019
- 2019-01-03 HR HRP20190023TT patent/HRP20190023T1/hr unknown
- 2019-08-08 HR HRP20191437 patent/HRP20191437T1/hr unknown
-
2020
- 2020-04-17 US US16/851,260 patent/US11291708B2/en active Active
- 2020-06-15 JP JP2020102938A patent/JP7309660B2/ja active Active
-
2021
- 2021-02-18 HR HRP20210277TT patent/HRP20210277T1/hr unknown
- 2021-05-10 HR HRP20210722TT patent/HRP20210722T1/hr unknown
-
2022
- 2022-03-30 US US17/709,305 patent/US20220370567A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110411A patent/JP2023134561A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191437T1 (hr) | Sastav za kontroliranu stimulaciju jajnika | |
| HRP20210669T1 (hr) | Režim doziranja povezan s injektibilnim dugodjelujućim paliperidon esterima | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| BR112014029208A2 (pt) | formulação para implante de paliperidona | |
| NZ767296A (en) | Liquid inhalation formulation comprising rpl554 | |
| BR112018000592A2 (pt) | composição de desbloqueio de nariz congestionado tendo atividade antiviral | |
| HRP20171446T1 (hr) | Topikalni antimikrobni dermatološki pripravak | |
| HRP20240013T1 (hr) | Menotropin za liječenje neplodnosti | |
| EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| WO2015051001A3 (en) | Composition and method for therapeutic agent delivery during pregnancy | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| HRP20181079T1 (hr) | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja | |
| EA201800266A1 (ru) | Антивирусная фармацевтическая композиция | |
| JP2014520874A5 (hr) | ||
| BR112015029709A2 (pt) | dihidroetorfina para o fornecimento de alívio da dor e anestesia | |
| BR112015014092A2 (pt) | administração oral transmucosal de acetato de glatirâmer | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| HRP20220896T1 (hr) | Liofilizirana farmaceutska formulacija i njena upotreba | |
| Santiago et al. | Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. | |
| HRP20211696T1 (hr) | Postupak izrade fluoriranih olefina | |
| HRP20211802T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika |